$1.675
+0.123 (+7.37%)At close
ACON News
ACON Events
Aclarion Publishes Nociscan Study Results with 87% Identification Rate
Aclarion announced the publication of an independent, peer-reviewed study in the European Spine Journal. Conducted by the London Spine Clinic, the study evaluated Nociscan against low-pressure provocative discography, the invasive procedure long considered the reference standard for identifying painful discs. The study compared the non-invasive Nociscan to discography in twenty consecutive patients being evaluated for surgical treatment, across 55 lumbar discs. Nociscan findings successfully identified painful discs, agreeing with discography in up to 87% of discs under a moderate threshold. At the study site, a three-disc Nociscan exam costs about GBP 2,040, versus roughly GBP 2,775 for an equivalent discogram. The authors, who noted the study's limited sample size, said larger, multi-center studies are being organized to build on the findings. "An agreement rate of up to 87% with an imperfect reference standard is a strong signal and exactly the kind of independent, real-world evidence that builds the case for physician adoption and payor support for Nociscan," said Ryan Bond, chief strategy officer.
Aclarion Reports 85% Year-over-Year Scan Volume Growth in Q3
Aclarion announced the publication of a shareholder letter from CEO Brent Ness covering Q3. The company reported 85% year-over-year scan volume growth in Q3, contributing to 117% growth for the nine months ended September 30. The European Spine Journal published peer-reviewed data supporting magnetic resonance spectroscopy as a potential viable alternative to provocative discography. The CLARITY trial expanded to eleven clinical sites with updated enrollment criteria to accelerate recruitment. Overall CLARITY trial duration remains on track, with an update on enrollment progress and anticipated initial readout timing by year-end. The company has $14.2M in cash, providing anticipated runway into the second half of 2027 and resources to fully fund the 300-patient CLARITY trial. "The third quarter was a strong one for Aclarion, reflecting the growing interest among physicians in what Nociscan can offer their patients with chronic low back pain," said Brent Ness, CEO.
Aclarion Announces NYU Langone Health as New Clinical Site in CLARITY Trial
Aclarion announced NYU Langone Health as a new clinical site in its CLARITY trial. The CLARITY study is designed to demonstrate Nociscan's clinical and economic value in spine surgery.
Aclarion Launches CLARITY Clinical Trial at University of Arizona
Aclarion announced the University of Arizona College of Medicine in Phoenix as a new clinical site in its CLARITY trial. The CLARITY study is designed to demonstrate Nociscan's clinical and economic value in spine surgery. The University of Arizona College of Medicine in Phoenix joins a growing network of high-volume CLARITY trial sites including Johns Hopkins University, Northwestern Medicine, Advocate Aurora Research Institute, Texas Back Institute, Keck Medicine at USC, UHealth, Scripps Health, Lanman Spinal Neurosurgery, and Texas Spine Care Center. The CLARITY trial is a 300-patient, prospective, randomized, multi-center study evaluating Nociscan in patients undergoing surgical treatment for discogenic low back pain. The primary endpoint is change in back pain as measured on a 100mm VAS Back at 12 months compared to baseline, with several secondary endpoints collected. The company anticipates having an initial internal data readout and an expected public disclosure of early interim results in Q4 2026. Nicholas Theodore, chairman of neurosurgery at University of Arizona College of Medicine in Phoenix at Banner University Medical Center Phoenix, serves as principal investigator of the CLARITY trial.
Aclarion Receives USPTO Allowance for Multi-Voxel Lumbar Disc Evaluation Patent
Aclarion announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application titled "Multi-Voxel Prescription for Lumbar Disc Evaluation." The allowed claims address a significant efficiency and quality challenge in MRS-based disc evaluation. By displaying both plan and shifted voxel locations during scan prescription, the innovation is designed to reduce the trial-and-error associated with voxel positioning, minimize the need for multiple scan series when optimal placement is uncertain, and lower the chance of a repeat study due to suboptimal voxel placement. Together, these improvements are designed to deliver a more efficient and consistent scan experience.
Related articles
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.